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The proceedings of the 3rd Annual Deep Brain Stimulation Think Tank summarize
the most contemporary clinical, electrophysiological, imaging, and computational
work on DBS for the treatment of neurological and neuropsychiatric disease.
Significant innovations of the past year are emphasized. The Think Tank’s contributors
represent a unique multidisciplinary ensemble of expert neurologists, neurosurgeons,
neuropsychologists, psychiatrists, scientists, engineers, and members of industry.
Presentations and discussions covered a broad range of topics, including policy and
advocacy considerations for the future of DBS, connectomic approaches to DBS
targeting, developments in electrophysiology and related strides toward responsive DBS
systems, and recent developments in sensor and device technologies.
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INTRODUCTION
The Third Annual Deep Brain Stimulation (DBS) Think Tank
convened at the University of Florida’s Research and Academic
Center in Orlando, FL, on March 18-20, 2015. This report
provides a summary of the conference sessions, which addressed
the most current research, clinical, ethical and policy work
on DBS for the treatment of neurological and psychiatric
disease. DBS research and its clinical translation incur wide
ranging, complex issues that necessitate ongoing frank discourse
and exchange of ideas among the multi-disciplinary group of
neurologists, neurosurgeons, neuropsychologists, psychiatrists,
scientists, engineers, and ethicists developing and engaging
DBS in research and clinical practice. The DBS Think Tank
aims to provide an annual forum where contemporary issues,
innovations, and challenges of the research and use of DBS are
shared, discussed, and debated. Presentations and discussions
addressed policy and advocacy considerations for the continued
advancement of DBS, connectomic approaches to DBS targeting,
developments in electrophysiology and related progress in
responsive DBS systems, and recent innovation in sensor- and
stimulation-device technologies.
The field continues to advance at an impressive pace.
Our hope is that this meeting promotes awareness among
stakeholders in DBS of currently unresolved and newly emerging
issues, so as to ultimately strengthen the field and better serve
patients. As in previous years, the meeting was conducted in a
“think tank” style; speakers presented analyses of critical issues
to foster dialog in subsequent discussions. The nature of this
think tank format implies that this is not an evidence-based
overview of developments in DBS; rather, it is a report of on-
going developments that have been advancing this dynamic field
and discussion of obstacles hindering further advancement and
potential solutions. This summary includes key points of both the
presentations and the follow-up discussions.
POLICY AND ADVOCACY FOR THE
FUTURE OF DBS
Viability of a DBS Industry Roadmap and
Consortium
An industry roadmap process, organization, success factors,
and typical and expected outcomes were discussed, using the
Abbreviations: DBS, deep brain stimulation; FDA, Food and Drug
Administration; IIR, investigator-initiated research; IDE, investigational device
exemption; NIH, National Institutes of Health; RoR, right of reference; SEEG,
stereoencephalography; MRI, magnetic resonance imaging; DTI, diffusion
tensor imaging; FA, fractional anisotropy; MCT, modulated circuit tractography;
SAS, subtraction activated SPECT; fcMRI, functional connectivity magnetic
resonance imaging; TAM, tractography activation models; PD, Parkinson’s
disease; IPG, implantable pulse generator; MICC, multiple independent
current control; HIFU, high intensity focused ultrasound; LFP, local field
potential; ECoG, electrocorticography; STN, subthalamic nucleus; ViM, ventralis
intermedius; TS, Tourette’s syndrome; CM-PF, centromedian parafascicular
nucleus of the thalamus; SVM, support vector machine; SC, subcallosal
cingulate gyrus; TRD, treatment resistant depression; PFG, prefrontal gyrus;
EEG, electroencephalography; LHb, lateral habenula; ECT, electroconvulsive
therapy; CSF, cerebrospinal fluid; PTSD, post-traumatic stress disorder; CAPS,
clinican-administered PTSD scale; BLn, basolateral nucleus of the amygdala.
semiconductor technology roadmap as a prior example of
successful effort (Spencer and Seidel, 1995; Schaller, 2001).
Industry roadmaps provide a dynamic and evolving collaborative
technology management process for determining critical needs
and drivers, identifying technology and manufacturing targets,
and assessing and modeling potential solutions to focus an
industry community. They can also provide direction toward
consensus-based resolution of needs and problems within
specific timeframes (Rathore, 2009; Cartreine et al., 2010;
Qattan et al., 2012; Finch et al., 2014). Such “road mapping”
has existed within corporations and organizations for decades.
Industry-wide roadmaps are versions of the corporate process
that can effectively be used to identify gaps in solutions
for common precompetitive challenges; suggest methods and
programs to resolve those gaps, and address lead-time issues by
indicating timeframes of opportunities for facilities, materials,
and equipment development within a supply chain community
(Garcia and Bray, 1997). Implementation can occur within
organizations in the competitive space, thereby contributing to
the growth of industry, by generating positive outcomes inclusive
of strategic and tactical partnerships throughout the industry.
DBS is being used to mitigate signs and symptoms of an
increasing range of neuropsychiatric disorders. In this way, DBS
has attained considerable success in treating a greater number
of patients, and in turn, fostered increased public awareness,
receptivity and demand for this technology.
The investment and success of DBS has fortified the
viability of key technological, commercial, and clinical
aspects of neurotechnology and are contributing to the
continued expansion, development, and success of the field
of neurotechnology in general and the use of DBS in medical
practice in particular. As a result, there is substantial energy and
investment to broaden the applications of DBS and to increase
the capability and complexity of DBS systems. The question
of whether and how the DBS industry would be best served
by a technology roadmap and/or consortium may reflect the
nature and extent of the common challenges presently impeding
technology advancement and deployment. The field is laden
with numerous issues, including increasing system complexity
(e.g., increasing interfaces and channel count, telemetry
bandwidth, recording and stimulation capability, etc.), variable
biocompatibility, packaging challenges (i.e., demands for smaller
size units with greater power efficiency and battery capacity), a
proliferation of potential brain targets and indications, and these
are reflected in—and foster—increasing regulatory requirements.
Figure 1 presents an overview of expert perceptions of the state
of maturity of DBS relative to other neurotechnologies, solicited
from participants at the think tank in an anonymous poll.
Implementation of industry-wide standards can evoke both
positive and negative effects for different stakeholders. For
example, on one hand growing mandated regulatory standards
can result in longer development times and higher development
costs. On the other hand, such standards can fortify the integrity,
efficacy, and safety of DBS technology in use, particularly now
as the applications of DBS are expanding tremendously. In
addition, the use of standards could actually lower barriers to
market entry as certain components of DBS systems become
more common commodities (e.g., the implanted pulse generator,
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FIGURE 1 | (A) A conceptual model of stages in technology development. (B) Results of survey evaluating participants’ perceptions of neurotechnology
development. Participants in the Think Tank were asked to submit examples of current or emerging neurotechnologies. A list was subsequently compiled and
participants were asked to indicate where they believed each of the items ranked in terms of the six stages shown in (B). Survey responses were averaged and the
item was subsequently placed in the category corresponding to the nearest whole number.
wireless telemetry). If regulatory processes at the Food and
Drug Administration (FDA) related to DBS systems evolve to
approve key target-agnostic DBS system blocks or components,
rather than entire systems designed for specific anatomical
targets, it could significantly increase the rate of neurotechnology
innovation. Specifically, such new regulatory processes would
support the efforts of smaller companies, with novel algorithmic,
anatomical target, and neural-interface concepts, to more quickly
deliver solutions to an increasing diversity of patient populations,
including those that are smaller and thus less economically
appealing to the existing medical-design manufacturers.
More attention is required to assess the potential viability
of industry-wide roadmaps and consortia to resolve these
issues.
Policy to Support Physician Initiated
Research and Innovation
Physician investigator-initiated research (IIR) is generally
regarded as conferring considerable advantages to DBS research
compared to industry-sponsored studies. Physicians are more
likely than industry to sponsor research focused on orphan
and small disease populations, and increasing IIR in DBS
would diversify and broaden ideas focusing upon the current
challenges—and opportunities—in the field (Rossi P. J. et al.,
2014). Moreover, as a group, physician researchers also have
a longer time horizon for assessing outcomes and adding
knowledge than most industry sponsors, which can lead to
different and uniquely valuable types of studies. However,
anecdotal evidence from physician researchers performing DBS
trials suggests that significant regulatory burdens are slowing the
pace of IIR research, and could be discouraging physicians from
participating in such efforts (Rossi P. J. et al., 2014).
A case study providing an overview of the timeline and
resources required to meet regulatory requirements for a DBS
clinical trial was presented (Kelly et al., 2014). Financial costs
for FDA-compliant data management were estimated at $100,000
USD for a 10 patient pilot study. Appropriate data management
is critically important for both enabling maximum use of
any and all information, and for protecting the privacy of
patients and the integrity of the research. However, the costs of
FDA-compliant data management substantially reduced funds
available for performing the study. Regulatory consultants and
support staff to interface with the FDA and to insure that all
necessary requirements for the investigational device exemption
(IDE) were met also contributed to overall regulatory costs,
which in the case study were∼$75,000 per year. It was noted that
such costs are prohibitive to many “stand-alone” investigators
without federal funding or institutional resource sharing.
While industry-sponsorship of a study is possible for certain
indications, such support is unlikely for research involving
orphan disease populations that represent a small market share
of potential consumers. Time costs were also significant; in the
case study presented, it took three (3) years from approval of the
NIH funding to the time that the first patient was enrolled in the
trial. Time costs to the investigator also include dedicated efforts
preparing regulatory paperwork. For example, it was estimated
that the amount of hours required to prepare documentation
for submission of an IDE was equivalent to the time required to
prepare three (3) NIH R-01 grant proposals.
Even given these barriers to physician-initiated DBS research,
it was emphasized that physicians are not seeking “less
regulation” but instead are calling for regulatory reform. In
this light, it was recommended that practices such as data
review, process auditing, and unannounced site visits would
be welcomed and could be increased, while processes related
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to documentation could be streamlined. Specifically, it was
recommended that a FDA-approved template for DBS-related
IDEs could guide investigators to more efficiently dedicate
time and resources to the components definitively required for
this type of research. In addition, it was recommended that
the right of reference (RoR) process be reformed. Currently,
RoR requires that industry partners approve studies that
use their devices; this approval is a means of protecting
commercial intellectual property and corporate assets and
providing protection from litigation. It was suggested that this
process could be reformed by indemnifying companies from
the consequences of an investigator’s FDA-approved off-label
use of corporate intellectual property. This reform would center
responsibility for the scope and conduct of research upon the
physician, rather than the industrial sponsor. In turn, this
would enable physicians’ control over clinical studies and, at
the same time, incur benefits to industry by no longer holding
industry partners accountable for reviewing (and ultimately
deciding upon) research proposals. Still, this reform may not
resolve device manufacturers’ concerns about a potential loss of
confidence in their brand should a poor outcome occur.
The DBS field is becoming increasingly competitive, with
potentially sizeable prizes, and sizeable risks. Achieving a leftward
shift in the time course for IIR will require, attention to
the benefits and burdens incurred in biomedical, ethical, and
legal domains. Toward this end, a multi-step paradigm for
comprehensively addressing critical issues and, importantly,
guide forward progress in DBS research and its clinical
translation was described and recommended. First, an overall
“6-R” stance was advocated, which encourages responsibility for:
assessment of capabilities and limitations of DBS in treatment of
particular neuropsychiatric conditions, research to evaluate DBS
effects in practice, regulation, responsivity to incurred burdens
and harms and revision of DBS technology and techniques, and
regulatory process, as necessary. Meeting these responsibilities
invokes a “6-W” set of questions that can be used to define the
parameters of use, and “6-Cs” that must be addressed in order
to establish ethical probity in use (Giordano, 2015). Details of
the “6-R, 6-W, 6-C” model for the ethical development of DBS
technology are presented in Figure 2.
While the need for continuity of care for patients involved
in experimental DBS interventions is clear from ethical and
clinical perspectives, the actual provision of such longitudinal
care has proven to be challenging in practice (Rossi P. et al.,
2014). One vexing recurrent issue is that insurance providers
occasionally decline reimbursing costs for off-label DBS, despite
granting “pre-approval” in a peer-to-peer review process with the
insurance company’s medical directors.
Given the increasing diversity of DBS approaches, cumulative
data aggregation, sharing, assimilation and synthesis will
be increasingly important to the iterative assessment and
improvement of the field. Toward these ends recommendation
was made to establish a common database for DBS research and
clinical outcomes, although the question was posed how—and
through which entity or institution—such a common database
would be established, hosted and curated (Giordano, 2012,
2014). Modification of extant systems, and development of new
information management frameworks will be required to collect
and integrate, support and sustain the wide distribution of
many types and levels of data. Such approaches should: establish
a common data format, optimize harvesting, aggregation and
synthesis, establish checking systems to assess and characterize
the type and quality of data, maximize accessibility and ensure the
source of data, and enable retraction of data that are inaccurate
or in need of revision for currency. In light of the increasing
number and internationality of IIR DBS studies, it will also be
important to address issues and questions of intellectual property
and proprietary use (Brindley and Giordano, 2014). To fortify IP,
provenance, attribution (and relative indemnities), and data use
and sharing agreements will need to be implemented to achieve a
dynamic repository that supports the range of intended uses for
these data (clinical care, training, and research).
Highlights
1. The DBS industry may be served by a roadmap and/or
consortium to address common challenges that are impeding
novel technology development and deployment at present and
in the near future.
2. Valuable investigator initiated research (IIR) could be
strengthened by regulatory reform emphasizing data
review, process auditing, and unannounced site visits while
streamlining processes related to documentation.
3. FDA-approved template(s) for DBS-related investigational
device exemptions (IDEs) could guide investigators to more
efficiently dedicate time and resources.
4. There is an urgent need to establish databases for DBS
research-related purposes.
5. Continuity of care concerns for patients involved in
investigational DBS procedures must be considered.
INNOVATIVE TECHNIQUES AND
TECHNOLOGIES IN DBS
Functional Connectivity Tools to Guide
Stimulation for Epilepsy
A critical step toward optimizing direct modulation of
refractory focal-onset epilepsy is to effectively interface depth
electrodes with complex epileptogenic brain circuits. Some novel
approaches are currently being exploited to achieve this goal.
It was recently shown that a correlation-based measure of
functional connectivity could be used to identify epileptogenic
zones from intracranial stereoencephalography (SEEG) signals
and that this information can be used to predict the outcome of
lobectomy in intractable temporal lobe epilepsy (Antony et al.,
2013). Indeed, patients with weakly connected, homogenous
networks responded less favorably to temporal lobectomy. These
findings suggest the value of such SEEG-based functional
connectivity modeling in predicting the outcomes of depth
electrode placement for epilepsy (Gonzalez-Martinez et al.,
2013).
In addition, the FDA recently approved a depth electrode
system as an adjunctive therapy for individuals with refractory
focal-onset epilepsy with two epileptogenic sources. A novel
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FIGURE 2 | Overview of the “6-R, 6-W, 6-C” model for the ethical development of DBS technology.
pre-implant depth electrode placement planning system has
been shown to enable the propagation of therapeutic current
to communicating distant epileptogenic sources. The pre-
implantation planning process consisted of several components:
(1) structural magnetic resonance imaging (MRI) and diffusion
tensor imaging (DTI) datasets; (2) computation of the induced
electric potential surrounding the electrode contacts using a finite
element method; (3) analysis of the effect of the electric field-
dependent FA (fractional anisotropy) model on depolarizing
axon bundles as identified by high-resolution DTI; and (4)
predicting distant cortical activation by strategically placing the
FA volume seeds to create a modulated circuit tractography
(MCT) map. The pre-implant MCT map was then used as a
targeting template for placing up to two depth leads intra-
operatively. This planning system was validated via subtraction
activated SPECT (SAS), which is a perfusion imaging technique
that captures stimulation induced transient changes in cerebral
blood flow. SAS was utilized post-implantation to validate in
vivo, the maximal extent of epileptogenic regions influenced by
stimulation therapy.
Functional Connectivity Tools Enable
Personalized DBS
The effect of focal brain stimulation is not limited to the region
targeted and a DBS current can propagate through anatomical
connections to influence distributed neural networks in the brain.
Emerging techniques that can help DBS practitioners visualize
these networks are likely to prove valuable for understanding and
guiding brain stimulation. One imaging technique particularly
well suited to visualizing brain networks is resting state functional
connectivity magnetic resonance imaging (fcMRI) (Fox and
Raichle, 2007). This technique has already been demonstrated
to (1) identify thalamic DBS targets based on connectivity to
brain regions implicated in tremor (Anderson et al., 2011), (2)
link invasive and non-invasive brain stimulation sites across
14 different neurological and psychiatric diseases (Fox et al.,
2014), and (3) be safely applied in patients implanted with DBS
electrodes using special low-energy MRI sequences (Kahan et al.,
2014).
Another method that has emerged with considerable promise
is patient-specific tractography-activationmodels (TAMs), which
can enable the identification and visualization of white matter
pathways activated by brain stimulation. TAMs essentially
predict action potential generation in specific pathways. They
combine anatomical imaging data, probabilistic tractography
from the brain region surrounding the implanted DBS electrode,
models of the electrical fields generated by DBS parameter
settings, and cable models of axons (Lujan et al., 2013). TAMmay
lead to improved personalized surgical targeting and stimulation
parameter selection. TAM may also facilitate identification
of new DBS targets (Downes and Pouratian, 2014), and a
deeper understanding of the mechanisms underlying both the
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therapeutic and off-target effects of DBS (Riva-Posse et al., 2014;
Sweet et al., 2014).
Harnessing advances in neuroimaging techniques may also
play a role in re-evaluating conventional thinking in the field.
For example, with probabilistic diffusion tensor tractography, the
four anatomical targets for DBS in cluster headache described
as hypothalamic in literature were shown to be localized
to the midbrain tegmentum posterior to the hypothalamus.
Importantly, tractography also revealed common tracts across
these targets, which included projections to the ipsilateral
hypothalamus, reticular formation, and cerebellum (Clelland
et al., 2014). Collectively, these results can motivate a shift from
stimulation of specific brain targets to stimulation of specific
brain networks.
Investigating Lead Placement Variability
There can be considerable variability in DBS outcomes, and some
clinical trials have failed recently because of profound variability
in response rate across the patient cohort. This is evident even
in successful clinical trials. For example, in one of the larger
DBS trials in PD the standard deviation in clinical outcome
scores was roughly equal to the effect size (Deuschl et al., 2006).
Over the past 10 years computational models have been used
to characterize potential sources of variance in the way DBS is
applied (Grill et al., 2004; Johnson and McIntyre, 2008; Dorval
et al., 2009, 2010; Santaniello et al., 2011). In general, these studies
attempted to characterize how andwhere stimulation was applied
in each patient. With regard to the latter, one critical element
for both surgical planning and population research has been co-
registration of pre-operative patient MRI to a brain atlas. This
is performed prior to surgery to permit indirect targeting of
nuclei that have poor contrast on conventional imaging, and it
is performed after surgery so that regions of activation for each
patient can be expressed in a probabilistic atlas of outcomes
(Butson et al., 2011). During this process it has been observed
that lead locations often vary within and among surgical sites.
This observation has led to questions about errors that could
be introduced during atlas registration, and has motivated an
evaluation of the accuracy of this registration process. The
most important finding from this evaluation was that the
observed variability in lead location cannot be attributed to
errors introduced during atlas registration. In fact, three different
registration algorithms yielded virtually the same results. This
information supports the suggestion that the neuromodulation
community could benefit from wider adoption and acceptance of
open source registration algorithms, several of which have been
rigorously developed and tested.
Temporal Pattern of Stimulation as a New
Dimension of Therapeutic Innovation
Although DBS is an established therapy for the treatment of
movement disorders, debate persists about the mechanisms
by which high frequency stimulation reduces symptoms. This
probably results in a failure to achieve full optimization of the
therapy with maximal benefits and minimal side effects. Thus,
an improved understanding of therapeutic mechanisms will be
important to enable further innovations in DBS technique and
technology.
The cellular effects of DBS on neurons of the central nervous
system include simultaneous inhibition of the cell body and
activation of the axon (McIntyre et al., 2004). This finding
motivated the “informational lesion” hypothesis positing that
DBS masks pathological oscillatory activity by normalizing the
activity of neurons within the stimulated nucleus. The striking
parallel between the frequency-dependent effects of DBS on
regularizing the activity of model neurons and the clinical
effects on symptoms provides strong correlational evidence for
this hypothesis (Grill et al., 2004). The informational lesion
hypothesis has been tested in several recent experiments (Zimnik
et al., 2015). The changes in representation of kinematic
information in the firing patterns of neurons of the globus
pallidus and thalamus that occurred during DBS indicate that
effective DBS produces at least a partial disruption of neural
information (Agnesi et al., 2013).
In contrast, a more recent study concluded that DBS does not
disrupt information transmission in the basal ganglia (Zimnik
et al., 2015). However, the currents used in this study were orders
of magnitude smaller than those required for positive effects on
symptoms, and therefore the effects of DBS on neuronal activity
were substantially underestimated. Using a highly innovative
paradigm to render a temporary direct connection to the
brain lead during surgical replacement of the implantable pulse
generator (IPG) enabled another test of this hypothesis (Swan
et al., 2014). Random patterns of subthalamic nucleus DBS, even
when delivered at a high average frequency (130 Hz), were not
effective in relieving bradykinesia in patients with Parkinson’s
disease. These findings reinforced the potential importance of
regularization (rather than complete disruption) of neuronal
activity for the effectiveness of DBS (Dorval et al., 2010).
The finding that the effects of DBS were dependent on the
temporal pattern of stimulation, in addition to the frequency of
stimulation, inspired the design and testing of novel temporal
patterns of DBS. Patterns were developed that treat the symptoms
of Parkinson’s disease (PD) more effectively than conventional
regularly patterned DBS (Brocker et al., 2013). or alternatively
enabled equivalent treatment of symptoms but with a substantial
reduction in the required energy. This latter innovation is
an important consideration for the size, recharge frequency,
and battery life of implanted pulse generators. Collectively, the
results demonstrated the utility of an entirely new dimension of
neural stimulation parameters—the timing between stimulation
pulses—to increase the efficacy and efficiency of stimulation.
Advancements in Lead Design
Emerging DBS device technology will enable controlling
of stimulation fields. Three novel lead designs—all with
uniquely engineered approaches to achieving this objective—
were presented. Two of the presented leads feature electrodes
segmented radially about the lead, in contrast with existing leads
that are segmented only along the long axis of the lead. The
third lead featured an extended span, and brings with it a new
kind of current control to DBS. These new leads will allow the
stimulating currents to be programmed in order to preferentially
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stimulate therapeutic targets and avoid stimulating areas prone
to side effects. The importance of tuning and directing the
stimulating field is based on the observation that electrodes
are occasionally sub-optimally placed (Okun et al., 2005) and
sometimes quite far from the intended target (Ellis et al., 2008).
All three of the lead designs are currently being evaluated
in various clinical trials (Contarino et al., 2014; Pollo et al.,
2014; Vitek and Starr, 2015). The use of directional electrodes
can improve DBS outcomes when electrodes are sub-optimally
placed. Preliminary data presented at the Think Tank indicated
that targeted stimulation with these approaches is promising,
although the long-term benefits of the “directional” leads remain
to be demonstrated, particularly in a chronic study. Figure 3
provides a detailed comparison of these new lead designs.
One lead under investigation (Medtronic-Sapiens) possesses
an advanced multiplexer unit that supports a total of 40
electrodes and a span of 7.41 mm. With 10 rows of 4 electrodes
per row, and alternating rows offset by 45◦, 8 radial electrode
directions are possible. Stimulation can be further shaped and
aimed radially by choosing various combinations of active
electrodes and splitting the current between them; however,
details are not yet public regarding how electrodes may be
combined and programmed. Additionally, recording of local field
potentials (LFPs) is possible from each of the 40 electrodes—
potentially yielding spatiotemporal information on pathologic
neuronal activity. Preliminary intraoperative testing of this
system suggests that it may be possible to utilize intraoperative
LFP recordings to assess the effect of stimulation in different
electrode combinations and current settings on pathological
subthalamic electrical activity (Bour et al., 2015). This field
shaping capability can possibly avoid stimulation of unwanted
regions and enhance engagement of target areas (Barbe et al.,
2014).
Another recently tested lead (Aleva) has a total of eight
electrodes (span, 5.5 mm): two are the traditional ring electrodes
and the remaining two rings are divided into three segments
each, allowing for directional current delivery through each
segment (Chase, 2014; Pollo et al., 2014). The electrode corners
are rounded so as to avoid “hot spots.” Clinical data suggest that
this directional lead, when tested in the acute setting in either the
subthalamic nucleus (STN) or the ventralis intermedius (VIM)
thalamus, can improve the therapeutic index, i.e., enlarge the
window between therapeutic effect and adverse effects, and also
may possibly use less current to achieve the same therapeutic
benefits (Chase, 2014; Pollo et al., 2014).
Another lead (Boston Scientific DB-2201; currently
undergoing clinical evaluation in the United States) also
possesses eight electrodes (15.5 mm span), current on each
of which can be precisely controlled, as the IPG is capable of
current steering. The aim of this design, also referred to as
Multiple Independent Current Control (MICC), is to achieve
more precise targeting of stimulation by enhancing control of
the therapeutic electric field. As the IPG associated with this
lead is a current control design, it should theoretically enable
more stable stimulation. By reducing variability in impedance
and permitting the effective use of lower pulse widths, it should
also be possible to expand the therapeutic window of effective
current amplitudes. Results of a European trial have shown
clinical outcomes comparable to existing leads, and during the
trial over 70% of programmers utilized the current steering
feature (although motivations for this use have not yet been
evaluated; Timmermann et al., 2015). The system also has
cordless recharging, and the rechargeable IPG utilizes cero
volt technology, which helps prevent substantial loss in battery
capacity following frequent and/or full discharges. Future
capabilities that could be co-deployed with this lead were
discussed, such as computer-guided distribution of current
across contacts for an optimized or informed programming.
Non-DBS Technology Impacting the Field:
Focused Ultrasound
In addition to addressing important improvements in DBS
system technology, the Think Tank sought to identify “non-DBS”
approaches that could impact the DBS field. In this regard, the
use of transcranial high intensity focused ultrasound (HIFU)
for treatment of movement disorders was reviewed (Dallapiazza
et al., 2014). While effective, stereotactic lesioning of the brain
for the treatment of movement disorders has been largely
abandoned with the development of DBS (Dallapiazza et al.,
2015). However, progress in transcranial MR-guided focused
ultrasound technology has renewed an interest in stereotactic
lesioning mainly because of the potential for continuous MRI-
guidance of an “incisionless” thalamotomy (Wang et al., 2015).
Three pilot studies at different institutions have demonstrated
significant improvements in hand tremor in patients with severe
essential tremor following focused ultrasound thalamotomy
(Elias et al., 2013; Wintermark et al., 2014a,b). These studies have
suggested functional improvements in activities, disabilities, and
quality of life with minimal morbidity. Furthermore, transcranial
ultrasound at low intensities can be used to manipulate deep
brain circuitry through non-invasive brain mapping prior to
lesioning. Clinical trials of HIFU for mapping neural circuitry
and treating in essential tremor and PD are currently ongoing.
Proponents of HIFU further highlight that an incision and
burr hole are not required to perform the procedure, offering
a “lower-cost, less invasive” alternative to DBS that eliminates
both the risks of penetrating the brain and the inconvenience
and costs imposed by implanted hardware (Lipsman et al., 2013).
Dissenters believe this to be an oversimplification. Unlike DBS
surgery, HIFU requires the head to be completely shaved; patients
must remain awake during the procedure and must lie flat within
the MRI scanner for a few hours while the target is localized. The
MRI environment, while offering the potential for procedural
monitoring, can be difficult to work in and some patients cannot
tolerate these image-guided procedures. In comparison, DBS
targeting scans are obtained in just a fewminutes and patients are
positioned more comfortably during surgery. Most importantly,
HIFU is an ablative and irreversible lesion, and can result in
adverse effects especially when used bilaterally.
Direct comparisons of traditional (non-HIFU) thalamotomy
and thalamic DBS have already been performed (Tasker, 1998;
Schuurman et al., 2000; Pahwa et al., 2001). Three studies,
conducted at reputable centers in the U.S., Canada, and
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FIGURE 3 | Comparison of emerging DBS electrode lead technology. BSN, Boston Scientific Neuromodulation; STJ, St. Jude Medical; MDT, Medtronic.
Reference: St. Jude DBS Brochure 2010, St. Jude DBS Product Catalog 2011, Medtronic DBS 3387/3389 Lead Kit Manual.
Europe have all reached a similar conclusion. While initial
tremor control was comparable for the two interventions,
thalamic DBS was safer than thalamotomy, causing fewer
neurological complications and reducing the need for re-
operation in the event of tremor recurrence. Indeed, one
member of the University of Virginia HIFU cohort suffered
permanent dysesthesia (Elias et al., 2013), and a follow-up
study from that group suggests that tremor control may lessen
over time as the lesion shrinks in size (Wintermark et al.,
2014a). However, it is worth noting that ET can also become
refractory to or tolerant of DBS despite increasing currents
(Favilla et al., 2012). Clearly, there is a subset of patients who will
subjectively prefer HIFU to DBS; however, it remains unknown
whether HIFU ablation is objectively better or cheaper than
DBS of the thalamus or any other target. Moreover, there
are concerns over limitations of this technology including the
need for bilateral procedures, the safety profile, and the lack of
programmability.
Highlights
1. SEEG-based functional connectivity modeling is helping to
predict outcomes of depth electrode placement for epilepsy
(Gonzalez-Martinez et al., 2013).
2. Connectivity-based approaches, both functional and
structural, suggest that targeting brain networks rather
than individual brain sites may improve and personalize DBS.
3. Modifying the temporal pattern of DBS stimulation may offer
a new dimension to the therapy.
4. Emerging DBS lead designs incorporating radially segmented
electrodes and systems incorporating current steering will
enable greater specificity in brain circuit targeting and will
improve the benefit/side effect ratio of DBS therapy.
5. Stereotactic ablation with high frequency ultrasound is a less
invasive procedure compared to DBS, but carries considerable
limitations, including irreversibility and unilaterality.
CLOSING THE LOOP WITH LOCAL FIELD
POTENTIALS
Local Field Potentials Provide Insight into
Neuropsychiatric Disorders
DBS has shown promise as a therapy for neuropsychiatric
disorders; however, advances have been hindered by relatively
poor understanding of the neural networks involved in the
pathophysiology of these conditions. To address this gap, an
ongoing study by researchers at University of California San
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Francisco is investigating the mechanisms underlying depression
and anxiety in PD patients undergoing awake DBS surgery.
This population of patients is ideal for studying the circuits
involved in these depressive and anxious symptoms because they
frequently co-occur in varying degrees of severity in Parkinson’s
disease (Gallagher and Schrag, 2012). These symptoms may be
modulated by both DBS and dopamine replacement therapies
(Tan, 2012; Storch et al., 2013). High spatial resolution recordings
of neuronal activity are performed intraoperatively within brain
structures that have been shown to be involved in emotion
regulation and cognitive control. Field potentials are recorded
from the DBS lead (containing 4 electrode contacts) implanted
in the basal ganglia (either the subthalamic nucleus or globus
pallidus) and from an additional subdural electrode (containing
28 contacts, spaced 2mmapart) placed over the prefrontal cortex.
Cortical areas targeted include the dorsolateral/medial prefrontal
cortex, the orbitofrontal cortex, and the ventrolateral prefrontal
cortex. Recordings are performed while patients rest or perform
tasks that engage networks involved in emotion regulation
and cognitive control. In addition, cortical and subcortical
stimulation are used to modulate mood. To identify correlations
between neural physiology and symptom severity, depression,
mood, and anxiety are characterized both before the surgery
using a variety of validated scales, and during the surgery using
visual analog mood scales.
Preliminary results of these experiments in the prefrontal
cortex suggest that, similar to what has been observed in the
motor cortex (Shimamoto et al., 2013; Yang et al., 2014; de
Hemptinne et al., 2015), the prefrontal cortex is dominated
by beta oscillations that can be coupled to broadband gamma
activity (Hammond et al., 2007). It was found that the magnitude
of beta rhythm and phase-amplitude coupling varies between
patients. In addition, in few patients, it was shown that
stimulation delivered to the deepest contact of the DBS lead
can induce anxiety, and this effect on mood is associated with
a decrease in beta activity and an increase in broadband gamma.
Although preliminary, these findings suggest that both the beta
oscillations and broadband gamma activity might be relevant
to psychiatric symptoms, and that the excessive synchronization
observed in cortical-basal ganglia motor networks might also
occur in cortical-basal ganglia networks involved in emotion and
cognition.
Long-Term Cortical and Subcortical Local
Field Potentials (LFPs) in Parkinson’s
Disease
While DBS is an effective treatment for movement disorders
such as PD there are several ways that it might be improved.
The current approach is to deliver constant stimulation without
adjusting the therapy or controlling for the patient’s disease
state, medication status, or side effects. A goal of advancing DBS
therapy is to implement a “closed-loop” system where electrical
signals from the patient’s brain are used in real-time as feedback
to customize stimulation delivery. Closing the loop can be used to
reduce undesired side effects of stimulation and to extend battery
life, as well as to improve stimulation effectiveness.
An important step in the development of closed-loop DBS
for PD is the characterization of brain signals associated with
the disease-relevant network. A recent on-going study aimed at
identifying pathophysiological activity related to PD implanted
five patients with novel devices capable of both stimulating
and long-term recording and storing of LFP data. In this
study, patients are implanted with a DBS electrode in the STN
capable of both stimulation and sensing/recording electrical
activity. In addition, 4-contact electrocorticography (ECoG) strip
placed over the primary motor cortex (M1), which is used for
sensing/recording only. Each patient is tested multiple times,
both on and off medication, and on and off DBS. Preliminary
results reveal that in most cases, medication is associated with
a reduction in beta (13–30 Hz) power in the STN, while
no consistent changes in beta power are recorded from M1.
While these results support the importance of beta synchrony
throughout basal ganglia-thalamo-cortical loops in PD, they also
suggest that there is variability between patients, and that a
closed loop signal may need to be optimized on a patient-by-
patient basis, and/or that a combination of control signals may
be needed.
In addition to identifying markers that are of relevance
to hallmark PD symptoms, this study also aimed to assess
adverse effects associated with dopaminergic therapy such as the
dyskinesias. In two patients experiencing marked contralateral
arm dyskinesia, a consistent and reproducible emergence of a
narrow-band ∼70 Hz increase in cortical power was observed.
There was also increased coherence in the same frequency
range between STN and M1. Similar patterns of high frequency,
narrow-band activity has been previously observed in a rodent
model of dyskinesia (Halje et al., 2012), and these may be useful
for closed loop approaches.
Long-Term Cortical and Subcortical LFPs
in Tourette’s Syndrome
Tourette Syndrome (TS) is a paroxysmal neuropsychiatric
disorder characterized by involuntary movements and/or vocal
outbursts (i.e., - tics) typically preceded by a premonitory urge
(Cheung et al., 2007; Kenney et al., 2008). DBS has been used
to treat cases of severe and intractable TS (Almeida et al.,
2015). It is estimated that ∼120 TS patients worldwide have
been treated with DBS since 1999, and almost 48 published
studies report some degree of motor tic reduction (Schrock
et al., 2015). While initial trials have been promising, the
mechanisms subserving the effectiveness of DBS in reducing TS
signs and symptoms have yet to be identified. Current models
of TS hypothesize that thalamocortical-basal ganglia dysfunction
is a key network underlying many TS symptoms. Inhibitory
input from basal ganglia structures affecting the activity of
key thalamic nuclei likely plays a role in patterns of motor
behaviors. It may be that inhibition of basal ganglia structures
leads to disinhibition of thalamic nuclei, which ultimately evokes
initiation of tics (Perlmutter and Mink, 2006). Previous research
has demonstrated potential biomarkers of tics (Maling et al.,
2012; Bour et al., 2014). Building upon this work, the validity,
reliability and relative predictive value of these biomarkers, and
Frontiers in Neuroscience | www.frontiersin.org 9 April 2016 | Volume 10 | Article 119
Rossi et al. 3rd DBS Think Tank Proceedings
the development of an algorithm that can be used in the early
detection of tics was presented.
In the presented study, two patients with severe, medication
refractory TS were implanted with bilateral DBS devices. Depth
leads were placed in the centromedian-parafascicular nucleus of
the thalamus (CM-PF) and electrocorticography (ECOG) strips
were placed over the precentral gyrus. Experiments consisted
of separate interleaved trials in which patients were instructed
to (1) tic freely, (2) suppress tics (baseline), and (3) execute
volitional movements (shaking hands rapidly, opening and
closing hands, raising arms up, and down, talking). Data were
recorded intraoperatively and post-operatively. Intraoperative
recordings demonstrated that both significantly more low (1–10
Hz) and high (30–100 Hz) frequency CM-PF activity was present
during tics but not during volitional movements. A support
vector machine (SVM)- based detector (Temko et al., 2011;
Wissel et al., 2013) was constructed to investigate the relationship
between this activity and tics during each post-operative visit
(for a period of 6 months). Three types of tics were recorded
including simple, complex, and long complex tics. Long complex
tics were shown to be concurrent with a consistently detectable
thalamocortical signature. Short complex tics were more difficult
to detect than long complex tics, and simple tics were the most
difficult to detect. Acute trials of closed loop stimulation using
the human tic detector are currently underway.
Local Field Potentials and Depression
A confluence of information prompted exploration of the
subcallosal cingulate gyrus (SC) as a DBS target for treatment
resistant depression (TRD) (Lozano et al., 2008). Attempts
to reduce TRD with SC DBS have shown clinical benefit: a
recent study involving 10 patients showed significant response
and remission rates following SC DBS (Holtzheimer et al.,
2012). However, numerous other targets for TRD, including
the nucleus accumbens, dorsolateral prefrontal cortex, and the
lateral habenula, have been proposed and subsequently explored
in clinical studies, with many of these showing at least some
evidence of clinical benefit (Rosa and Lisanby, 2012). The
question then arises if and how these targets may be related. The
conceptualization of depression as a network disorder suggests
that neuromodulation at the purported origin as well as at
“nodes” of the network can be beneficial (Mayberg, 2009). TAMs
of patients who underwent SC DBS for depression demonstrate
significant differences between those who responded to therapy
and those who did not (Riva-Posse et al., 2014). Specifically, it
was shown that responders had greater tract coverage in critical
regions.
Recent work has focused on using this information to improve
DBS targeting. Prospective work is currently underway to utilize
DTI pre-operatively to plan lead placement. This approach has
been associated with an increase in the 6-month response rate
from 41 to 76%. An important next stage of research will be
to identify other markers that can confirm if a lead has been
placed in a location that would elicit maximal benefit. On-
going studies aimed at identifying physiological markers useful
in evaluating lead placement and predicting treatment response
were presented. These studies focused on intraoperative LFPs
from the DBS electrodes in conjunction with intraoperative
ECoG and electroencephalograhy (EEG). Previous studies have
identified changes in alpha rhythm in depression; the alpha band
frequency is increased in the left frontal lobe in depression (Saletu
et al., 2010) while alpha is decreased in the right prefrontal cortex
(PFC) (Bruder et al., 2001). Preliminary studies of intraoperative
LFPs from both ECoG and depth electrodes after stimulation at
“effective” contacts (determined by imaging) have demonstrated
decreases in the alpha and beta frequencies in the left PFC, as
well as a decrease in alpha and beta bands in the subgenual
cingulate.
Local Field Potentials and Strides Toward a
Closed-Loop DBS
DBS systems currently deployed in the clinic are “open-loop”
and do not take into account the potentially intermittent
nature of symptoms. By detect the neurophysiologic correlates
of symptoms such as tremor, we can determine not only
when stimulation may be necessary but also estimate the
intensity of stimulation needed. Stimulating only when
necessary can increase the battery life of the implanted
devices and reduce a patient’s exposure to unintended
effects.
A novel mobile, wireless platform for investigating closed-
loop DBS applications in ambulatory patients was presented
(Herron and Chizeck, 2014). The platform consisted of a
set of body-worn sensors communicating wirelessly to a
host application running on a smartphone or a personal
computer. Taking advantage of movement data including
inertial measurements, electromyography, and LFPs, these host
applications are capable of performing digital signal processing
and data fusion in order to make control decisions. These
control decisions can include enabling or disabling stimulation
or modifying individual stimulation parameters (voltage, pulse
width, frequency) in response to changes in neurological
symptoms (Herron et al., 2015). These control decisions are then
sent wirelessly to an external receiver that then relays packets
and control decisions to an implanted neurostimulator. This real-
time command link to the implanted device has enabled the
implementation of an integrated closed-loop DBS system.
This system confers several important benefits for both
research and patient care. Currently, studies are underway to
assess clinical performance of the system, and future studies
are being planned which utilize the wealth of consistent,
chronic data generated from the integrated system to
investigate neurological movement disorder, particularly
tremor.
Highlights
1. Chronic recording of FPs is permitting greater insight into
multiple neuropsychiatric disorders.
2. LFP-based research holds promise for the identification of
pathological brain signals that could serve as triggers for
responsive stimulation.
3. Closed loop systems are being tested which could use a variety
of signals in order to modulate therapy.
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INNOVATIVE TARGETS FOR NEW
INDICATIONS
Lateral Habenula as a Target for
Depression
In 2007, a non-human primate study provided the first
electrophysiological evidence that the lateral habenula (LHb)
played a role in the brain’s reward system. The study
demonstrated that reward was associated with suppression of
inhibitory input from the LHb and subsequent activation of
dopamine neurons, while the reverse was observed for non-
rewarding trials (Matsumoto and Hikosaka, 2007). That same
year, Alex Sartorius and Fritz Henn advanced the hypothesis
of over activation of the habenula in major depressive episodes
and argued that DBS of the lateral habenula could be beneficial
for TRD (Sartorius and Henn, 2007). More recent studies in
humans have corroborated the notion of LHb involvement
in the reward system (Salas et al., 2010), and, interestingly,
two case reports have since been published (2010, 2013)
showing remission of major depression under DBS of the LHb
(Sartorius et al., 2010; Kiening and Sartorius, 2013; Schneider
et al., 2013). Early results from an on-going open-label trial
of six patients undergoing habenular DBS for TRD were
presented. The hypothesis that patients who were responsive to
electroconvulsive therapy (ECT)—even if for a short duration—
could be “better” candidates for habenular DBS was proposed,
and is under investigation in the present study. As a DBS target,
the LHb poses unique challenges for electrode implantation—
among these is the proximity of the target to the third ventricle
and the resultant motion artifact observed in imaging studies
due to the pulsatile movement of the cerebro-spinal fluid (CSF).
Programming-related adverse events observed to date were
discussed. Upper extremity paresthesias occurred commonly,
although patients mostly habituated to this and the effect was
modifiable by gradually increasing the current. Oculomotor
abnormalities were also observed which limited current dosing,
and it was proposed that current steering could be useful in
limiting this side effect.
DBS of the Basolateral Nucleus of the
Amygdala for PTSD
Neuromodulation of the amygdala may prove beneficial in
disease processes where symptoms arise from the aberrant
assignment of an emotion to a specific event or context
(Langevin, 2012). In post-traumatic stress disorder (PTSD),
patients assign fear to benign situations, which may potentially
lead to avoidance behavior. Several neuroimaging studies
have demonstrated that the amygdalae of PTSD patients are
metabolically overactive during symptomatic episodes (Etkin and
Wager, 2007; Hughes and Shin, 2011). The level of activity within
the amygdala correlates with the severity of the symptoms as
measured by the clinician-administered PTSD scale (CAPS). An
important study by Koenigs and colleagues showed that Vietnam
veterans who suffered traumatic brain injury to the amygdala
never developed PTSD (Koenigs et al., 2008). These results
suggest that the amygdala plays a critical role in the production
of PTSD symptoms. Focal interference of amygdala activity
through DBSmay improve PTSD. Although its mechanism is not
fully understood, high frequency DBS is thought to functionally
inactivate a specific, gray matter target. It was previously shown
that DBS of the basolateral nucleus of the amygdala (BLn)
reduced the behavior associated with PTSD in a rodent model
(Langevin et al., 2010). A subsequent study in the same rodent
model demonstrated that BLn DBS was superior to paroxetine—
one of the drugs approved by the FDA to treat PTSD (Stidd
et al., 2013). These results led to the recent development of
a clinical trial to evaluate the feasibility and the safety of this
technique in PTSD patients (Koek et al., 2014). An overview
of the trial design was presented, as well as an overview of
the first surgical subject implanted. In addition, the targeting
technique and intra-operative microelectrode recording findings
were described. Consideration of the patient’s neuroanatomy is
critical because of the wide variation in size and shape of the
mesiotemporal structures.
DBS for Stroke
The concept of post-stroke neurostimulation does not focus on
modulation of the area damaged by ischemia, rather it is intended
to (1) augment the perilesional cortex or (2) modulate other
areas whose connectivity has been disrupted by the stroke. Direct
cortical stimulation as a means of enhancing excitability and
plasticity has been investigated (Alonso-Alonso et al., 2007), but
has failed to produce the intended benefits in clinical trials. One
possible reason for the failure of cortical stimulation was the
relationship between cortical axons and the source of stimulation
(Manola et al., 2005a,b). In rodent models, axonal arrangement
perpendicular to the cathode is predictable. However, in human
brains, axonal arrangement is less predictable, and it is possible
that axons were inhibited and excited in near equal proportions
during cortical stimulation interventions and the net effect
washed out. A novel approach to stroke therapy via DBS was
discussed; the intention was to stimulate natural fiber pathways
to the perilesional cortex in a way that mimics their native
function. Preliminary results of this design in a rodent model
were presented. Based on motor pathway fiber tracing by Dum
and Strick, a cerebellar target (lateral cerebellar nucleus) was
selected with the goal of modulating the dentatothalamocortical
pathway (Dum and Strick, 2002; Machado and Baker, 2012).
Stimulation of this target (particularly at 30 Hz) was shown to
evoke cortical excitability. A follow-up study tested the effect
of chronic 30 Hz DBS in this target on motor function in a
rodent model of stroke (Machado et al., 2013). Animals in the
stimulation group showed a significant improvement in motor
function compared with post-ischemia baseline performance as
well as in comparison with the non-stimulation group (Machado
et al., 2013). Moreover, perilesional synaptic density testing
showed that animals in the stimulation group had significantly
greater numbers of perilesional synapses. Preliminary results of
on-going studies of cytoarachitecture in these animals addressing
whether these observations reflect neurogenesis in addition
to synaptogenesis were also presented. Substantial discussion
surrounded the topic of the appropriate level of pre-clinical
evidence needed to justify early clinical translation studies.
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Highlights
1. Emerging research suggests the viability of DBS as a treatment
for new indications, including depression, PTSD, and stroke.
2. Research into novel targets for novel indications requires
hypotheses based on animal models (where possible), well-
designed clinical trials, and careful attention to potential off-
target effects, patient selection, and targeting considerations.
CONCLUSION
These proceedings represent the deliberations of the third
Annual Deep Brain Stimulation Think Tank. The group
addressed critical issues affecting the progress of the DBS field.
These issues span multiple domains, including regulatory and
ethical issues as well as study design. There are also important
barriers to advance electrophysiology and system engineering.
In discussing these challenges, participants in the Think Tank
proposed and discussed possible solutions.
Scientific, clinical, and engineering advances that could
transform the DBS field in the near future served as a primary
focus of the Think Tank. The meeting focused on recent
discoveries that may lead to transformative, not just incremental
change in DBS therapy. Participants discussed the broad range
of potential applications of the new knowledge, techniques, and
technologies presented; they also discussed ways in which these
advances could be fully exploited to rapidly advance to the next
generation of DBS therapy. The future of DBS will depend heavily
on building on these advances and on filling knowledge current
gaps.
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